4 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Thromboembolic Events in Total Knee Replacement Patients MAA868, Enoxaparin - Thrombotic Disorders | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-10-03 | 2020-10-08 | |
| Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli Apixaban, Placebo - Patent Foramen Ovale, Cardiac Implantable Electronic Device | Phase 2 | Withdrawn | Mayo Clinic | 2015-05-01 | 2018-11-16 | |
| Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age dabigatran etexilate - Venous Thromboembolism | Phase 2 | Withdrawn | Boehringer Ingelheim | 2013-01-01 | 2015-10-26 | |
| Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR) GW813893 - Venous Thromboembolism | Phase 2 | Withdrawn | GlaxoSmithKline | 2007-02-01 | 2013-04-04 |
Venous Thromboembolism (3) · Cognitive Dysfunction (1) · Embolism, Paradoxical (1) · Foramen Ovale, Patent (1) · Stroke (1)
Cardiovascular Diseases (4) · Embolism and Thrombosis (4) · Vascular Diseases (4) · Brain Diseases (1) · Cardiovascular Abnormalities (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Cognition Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Heart Septal Defects (1) · Heart Septal Defects, Atrial (1)
2-(5-chlorothien-2-yl)-N-(1-(1-methyl-2-(morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl)ethenesulfonamide (1) · Dabigatran (1) · Enoxaparin (1) · MAA868 (1) · apixaban (1)
Boehringer Ingelheim (1) · GlaxoSmithKline (1) · Mayo Clinic (1) · Novartis Pharmaceuticals (1)
United States (3)
Christopher DeSimone, MD (1) · Paul Friedman, MD (1) · Samuel Asirvatham, MD (1)
2017 (1)